Patents Examined by Laura Ann Essex
-
Patent number: 11969464Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 23, 2023Date of Patent: April 30, 2024Inventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
-
Patent number: 11970532Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.Type: GrantFiled: May 10, 2019Date of Patent: April 30, 2024Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Wonkyum Kim, Jeongwon Yoon, Junho Chung, Junyeong Jin, Eunhwoi You
-
Patent number: 11965035Abstract: The invention relates to an antibody which binds to chondroitin sulfate proteoglycan 5 (CSPG5) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.Type: GrantFiled: June 26, 2019Date of Patent: April 23, 2024Assignees: KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITYInventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Yuji Ito
-
Patent number: 11952409Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 24, 2023Date of Patent: April 9, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Jens Hukelmann, Heiko Schuster, Lena Wullkopf, Christoph Schraeder, Jens Fritsche, Daniel Johannes Kowalewski, Michael Roemer, Oliver Schoor
-
Patent number: 11939370Abstract: The present disclosure is directed to human antibodies binding to and neutralizing ebolavirus and methods for use thereof. A further embodiment involves a monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences. In yet another embodiment, there is provided a hybridoma or engineered cell encoding an antibody or antibody fragment. An additional embodiment comprises a vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences. In still a further embodiment, there is provided a method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with ebolavirus comprising delivering to said subject the antibody or antibody fragment.Type: GrantFiled: July 11, 2019Date of Patent: March 26, 2024Assignees: VANDERBILT UNIVERSITY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: James E. Crowe, Jr., Pavlo Gilchuk, Alexander Bukreyev
-
Patent number: 11919854Abstract: The present invention relates to compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts, and their use in therapy, particularly for the treatment of cancer or inflammatory diseases.Type: GrantFiled: March 29, 2019Date of Patent: March 5, 2024Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CHRU DE LILLE, UNIVERSITE COTE D'AZUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE LILLE, JUNIAInventors: Valérie Vouret, Laetitia Douguet, Alina Ghinet, Germain Homerin, Benoît Guy Marie Rigo, Davy Jérémy Baudelet, Xavier Dezitter, Régis Millet, Christophe Furman
-
Patent number: 11904003Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 17, 2023Date of Patent: February 20, 2024Assignee: Immatics Biotechnologies GMBHInventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
-
Patent number: 11896644Abstract: As disclosed herein, ?-arrestin1 and ?-arrestin2 levels are highly elevated in brains of FTLD-tau patients suggesting that both ?-arrestin1 and ?-arrestin2 are elevated in the brains of patients with AD and FLTD. The current work also shows that when ?-arrestin2 is overexpressed, tau levels become elevated. The data indicate that ?-arrestin2 reduces tau clearance by impairing p62-mediated autophagy, a role carried out by the oligomerized form of ?-arrestin2. Therefore, disclosed herein are ?-arrestin oligomerization inhibitors that can be used to prevent ?-arrestin oligomerization and therefore the accumulation of tau in cells, i.e. tauopathy. Also disclosed are methods of treating a tauopathy in a subject that involve administering to the subject a therapeutically effective amount of a ?-arrestin oligomerization inhibitor disclosed herein.Type: GrantFiled: February 8, 2021Date of Patent: February 13, 2024Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Jung A. Woo, Stephen Bryant Liggett, David E. Kang, Yu Chen, Eric Lewandowski
-
Patent number: 11897951Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.Type: GrantFiled: December 17, 2021Date of Patent: February 13, 2024Assignees: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Christian Asbrand, Nadine Biesemann, Ann Brigé, Sigrid Cornelis, Karen Heyninck, Eric Lorent, Shanna Van Zwam
-
Patent number: 11891427Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 29, 2021Date of Patent: February 6, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Jens Hukelmann, Heiko Schuster, Lena Wullkopf, Christoph Schraeder, Jens Fritsche, Daniel Johannes Kowalewski, Michael Roemer, Oliver Schoor
-
Patent number: 11884741Abstract: Disclosed is a method for producing a modified antibody, comprising: in a heavy chain of the antibody, changing at least one amino acid residue selected from the group consisting of 8th to 11th amino acid residues based on Kabat method to a cysteine residue, and changing at least one amino acid residue selected from the group consisting of 109th and 110th amino acid residues based on IMGT method to a cysteine residue; and recovering the modified antibody.Type: GrantFiled: February 22, 2021Date of Patent: January 30, 2024Assignee: SYSMEX CORPORATIONInventors: Tomofumi Nakada, Nobuyuki Ide
-
Patent number: 11884718Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.Type: GrantFiled: April 24, 2019Date of Patent: January 30, 2024Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israeli Deaconess Medical Center, Inc., The Government Of The United States As Represented By The Secretary Of The ArmyInventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce, Rajeshwer Singh Sankhala, Kathryn Elaine Stephenson
-
Patent number: 11873340Abstract: Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as systemic inflammatory response following central nervous system trauma.Type: GrantFiled: February 24, 2017Date of Patent: January 16, 2024Assignees: The University of Western Ontario, Eli Lilly and CompanyInventors: Gregory Dekaban, Arthur Brown, Lynne Weaver, Allan Barrett, Kristine Kikly
-
Patent number: 11873337Abstract: The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.Type: GrantFiled: June 26, 2019Date of Patent: January 16, 2024Assignees: KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITYInventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Takenao Yamada, Yuji Ito
-
Patent number: 11859005Abstract: The present disclosure relates to compounds that bind to human GITR, pharmaceutical compositions comprising such compounds, and methods of using such compounds.Type: GrantFiled: February 1, 2022Date of Patent: January 2, 2024Assignee: Eli Lilly and CompanyInventors: Petra Verdino, Paul Francis Cain, Melinda Ann Lacerte, Stacey Lynn Lee, Mark Andrew Wortinger
-
Patent number: 11851479Abstract: Compositions and methods for the detection and diagnosis of Bordetella pertussis are disclosed. Provided are antibodies, or antigen binding fragment thereof, specific for tracheal colonization factor A (TcfA). Also provided are compositions comprising an anti-TcfA antibody of the instant invention and a carrier; and methods for inhibiting, treating, and/or preventing pertussis and/or a B. pertussis infection in a subject in need thereof are provided, comprising administering an anti-TcfA antibody of the instant invention to the subject.Type: GrantFiled: June 18, 2019Date of Patent: December 26, 2023Assignee: DXDISCOVERY, INC.Inventor: Amanda Burnham-Marusich
-
Patent number: 11845791Abstract: The present disclosure is directed to human GDF-15-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect human GDF-15 and/or in methods of treating cancer or body weight loss, including cachexia, associated with over-expression of human GDF-15.Type: GrantFiled: March 7, 2022Date of Patent: December 19, 2023Assignee: MEDIMMUNE, LLCInventors: Claire Dobson, Fiona Cusdin, Darren Schofield, Peter Cariuk, Elaine Hurt, Margareta Ek, Carina Johansson, Jenny Sandmark
-
Patent number: 11845804Abstract: A third generation of CAR-CD30 T cells is for treatment of CD30+ Tumors such as lymphoid malignancies, leukemia, and solid tumors. A CD30 chimeric antigen receptor includes, from the N-terminus to the C? terminus, a signal peptide, which is linked by a first linker to an anti CD30 single chain antibody domain from AC10 hybridoma including the AC10 VL sequence and the AC10 VH sequence. The AC10 VL and VH sequences are linked by a second linker.Type: GrantFiled: March 12, 2019Date of Patent: December 19, 2023Assignee: OSPEDALE PEDIATRICO BAMBINO GESU'Inventors: Biagio De Angelis, Concetta Quintarelli, Ignazio Caruana, Franco Locatelli
-
Patent number: 11840568Abstract: The present invention relates to an antibody binding to lymphocyte activation gene-3 (LAG-3) and use thereof.Type: GrantFiled: April 1, 2019Date of Patent: December 12, 2023Assignee: MAB-VENTURE BIOPHARM CO., LTD.Inventors: Shaoxiong Wang, John L. Xu, Jing Zhao, Ming Wang, Juehua Xu, Fei Song
-
Patent number: 11833195Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 29, 2021Date of Patent: December 5, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor